Biogen Stock Price, News & Analysis (NASDAQ:BIIB)

$292.78 +7.97 (+2.80 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$292.78
Today's Range$285.60 - $294.24
52-Week Range$244.28 - $370.57
Volume2.54 million shs
Average Volume1.68 million shs
Market Capitalization$61.94 billion
P/E Ratio16.77
Dividend YieldN/A
Beta0.75

About Biogen (NASDAQ:BIIB)

Biogen logoBiogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:BIIB
CUSIP09062X10
Phone+1-781-4642000

Debt

Debt-to-Equity Ratio0.47%
Current Ratio2.34%
Quick Ratio2.07%

Price-To-Earnings

Trailing P/E Ratio16.7686139747995
Forward P/E Ratio11.77
P/E Growth1.49

Sales & Book Value

Annual Sales$12.27 billion
Price / Sales5.05
Cash Flow$27.70 per share
Price / Cash10.57
Book Value$59.55 per share
Price / Book4.92

Profitability

Trailing EPS$17.46
Net Income$2.54 billion
Net Margins20.69%
Return on Equity38.32%
Return on Assets20.72%

Miscellaneous

Employees7,300
Outstanding Shares211,560,000

Biogen (NASDAQ:BIIB) Frequently Asked Questions

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

How were Biogen's earnings last quarter?

Biogen Inc (NASDAQ:BIIB) announced its earnings results on Thursday, January, 25th. The biotechnology company reported $5.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.44 by $0.18. The biotechnology company had revenue of $3.31 billion for the quarter, compared to analyst estimates of $3.08 billion. Biogen had a return on equity of 38.32% and a net margin of 20.69%. The company's revenue for the quarter was up 15.1% compared to the same quarter last year. During the same quarter last year, the business earned $5.04 EPS. View Biogen's Earnings History.

When will Biogen make its next earnings announcement?

Biogen is scheduled to release their next quarterly earnings announcement on Tuesday, April, 24th 2018. View Earnings Estimates for Biogen.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY18 earnings guidance on Thursday, January, 25th. The company provided EPS guidance of $24.20-25.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $24.13. The company issued revenue guidance of $12.7-13.0 billion, compared to the consensus revenue estimate of $12.68 billion.

Where is Biogen's stock going? Where will Biogen's stock price be in 2018?

29 brokerages have issued 1-year price objectives for Biogen's stock. Their forecasts range from $279.00 to $433.00. On average, they expect Biogen's share price to reach $368.30 in the next twelve months. View Analyst Ratings for Biogen.

What are Wall Street analysts saying about Biogen stock?

Here are some recent quotes from research analysts about Biogen stock:

  • 1. Mizuho analysts commented, "We also note full year 2017 consensus is already above the company’s guidance on both top and bottom lines (guidance last updated in 2Q17) 1. Spinraza. We believe investors will continue to be focused on the performance of the Spinraza launch and information from management on uptake trends. At the recent JPM conference, BIIB commented that for Spinraza they see a benefit from the new launch period in large territories and then a moderate rate of growth, noting that they see reasonable growth in the US in the coming quarters and that a lot of the growth will come outside the US as new countries receive approvals. This was similar to commentary from management in the 3Q17 call. Consensus has 4Q over 3Q growth of 11% and 51% in the US and Ex-US for Spinraza." (1/18/2018)
  • 2. Cantor Fitzgerald analysts commented, "MS franchise appears poised for modest negative growth. A tepid patient population growth rate combined with encroaching competition from new agents means existing franchise assets may have achieved peak revenues already, in our opinion." (10/24/2017)
  • 3. Citigroup Inc analysts commented, "We're downgrading the stock to neutral from buy as we don't think the street fully appreciates Avexis competition and in coming 6-12 months we think MS pricing concerns in form of greater rebating get louder as we approach Gilenya losing patent and Celgene's Ozanimod launch," (10/23/2017)
  • 4. Stifel Nicolaus analysts commented, "gigantic" aducanumab phase 3 trial, which started in 2015 and was 50 percent enrolled in the second quarter of 2017, Shrader commented in his upgrade note. This should be seen as a "no news is good news" scenario as the Data and Safety Monitoring Board has likely seen a lot of data and hasn't reported anything negative.Second, Biogen's partner Eisai is set to report an interim outlook at its plaque-busting mAb that targets the form of Ab plaque thought to lead to neuronal destruction, the analyst continued. The only possible negative outcome would be strong plaque removal with no hints of cognitive benefit and any other result could either be very good or OK.Third, Biogen's often ignored stroke programs address a very large market. Of particular note, the company's Tysabri stoke program uncovered the "same cognitive and energy benefits in stroke patients that are routinely reported in MS patients" and turning this effect into a clinical endpoint that would be acceptable for the U.S. Food and Drug Administration is the likely next step.Finally, Ocrelizumab as part of the company's base business is "meh not mud," the analyst added. The therapy remains a drug with "remarkable anti inflammatory properties," but a commercial rollout will likely be "measured." (10/17/2017)
  • 5. Cowen Inc analysts commented, "Biogen reported Q1 revenues of $2.81B (+3% Y/Y, vs. consensus of $2.74B) and non-." (4/25/2017)

Who are some of Biogen's key competitors?

Who are Biogen's key executives?

Biogen's management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board (Age 68)
  • Michel Vounatsos, Chief Executive Officer, Director (Age 55)
  • Jeffrey D. Capello, Chief Financial Officer, Executive Vice President (Age 53)
  • Ginger Gregory Ph.D., Chief Human Resource Officer, Executive Vice President (Age 49)
  • Kenneth A. Di Pietro, Executive Vice President - Human Resources (Age 58)
  • Susan H. Alexander Esq., Executive Vice President, Chief Legal Officer and Corporate Secretary (Age 60)
  • Michael D. Ehlers M.D., Ph.D., Executive Vice President, Head - Research and Development (Age 48)
  • Chirfi Guindo, Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation
  • Adriana Karaboutis, Executive Vice President - Technology , Business Solutions and Corporate Affairs (Age 54)
  • Jean-Paul Kress M.D., Executive Vice President, President - International and Head of Global Therapeutic Operations (Age 51)

Who owns Biogen stock?

Biogen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.94%), Clearbridge Investments LLC (4.32%), Alliancebernstein L.P. (1.61%), Geode Capital Management LLC (1.16%), Bank of New York Mellon Corp (1.13%) and Jackson Square Partners LLC (0.98%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.

Who sold Biogen stock? Who is selling Biogen stock?

Biogen's stock was sold by a variety of institutional investors in the last quarter, including TIAA CREF Investment Management LLC, Assenagon Asset Management S.A., Candriam Luxembourg S.C.A., Jackson Square Partners LLC, Credit Agricole S A, BlackRock Inc., Teacher Retirement System of Texas and Clearbridge Investments LLC. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, Brian S Posner, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Insider Buying and Selling for Biogen.

Who bought Biogen stock? Who is buying Biogen stock?

Biogen's stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Amundi Pioneer Asset Management Inc., Robeco Institutional Asset Management B.V., Smith Asset Management Group LP, Los Angeles Capital Management & Equity Research Inc., American Century Companies Inc., ADAMCAPITAL Gestao de Recursos Ltda. and Teachers Advisors LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

How do I buy Biogen stock?

Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biogen's stock price today?

One share of Biogen stock can currently be purchased for approximately $292.78.

How big of a company is Biogen?

Biogen has a market capitalization of $61.94 billion and generates $12.27 billion in revenue each year. The biotechnology company earns $2.54 billion in net income (profit) each year or $17.46 on an earnings per share basis. Biogen employs 7,300 workers across the globe.

How can I contact Biogen?

Biogen's mailing address is 225 Binney St, CAMBRIDGE, MA 02142-1031, United States. The biotechnology company can be reached via phone at +1-781-4642000.


MarketBeat Community Rating for Biogen (BIIB)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,246 (Vote Outperform)
Underperform Votes:  729 (Vote Underperform)
Total Votes:  1,975
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biogen (NASDAQ:BIIB) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.722.752.682.67
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
12 Buy Rating(s)
2 Strong Buy Rating(s)
Consensus Price Target: $368.30$358.56$342.62$331.23
Price Target Upside: 23.02% upside1.36% upside10.86% upside16.20% upside

Biogen (NASDAQ:BIIB) Consensus Price Target History

Price Target History for Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2018ArgusDowngradeBuy -> HoldMediumView Rating Details
2/15/2018Canaccord GenuitySet Price TargetHold$350.00LowView Rating Details
2/15/2018William BlairReiterated RatingBuyLowView Rating Details
2/7/2018Credit Suisse GroupUpgradeBuy$384.00HighView Rating Details
2/8/2018JPMorgan Chase & Co.Reiterated RatingBuyHighView Rating Details
2/4/2018MizuhoReiterated RatingBuy -> Buy$400.00 -> $433.00HighView Rating Details
1/26/2018OppenheimerBoost Price TargetOutperform -> Buy$380.00 -> $400.00LowView Rating Details
1/26/2018Deutsche BankReiterated RatingBuy$373.00LowView Rating Details
1/26/2018Jefferies GroupReiterated RatingHoldMediumView Rating Details
1/26/2018Royal Bank of CanadaBoost Price TargetSector Perform$347.00HighView Rating Details
1/26/2018SunTrust BanksBoost Price TargetBuy$392.00HighView Rating Details
1/26/2018HC WainwrightReiterated RatingBuy -> Buy$340.00 -> $363.00HighView Rating Details
1/26/2018CowenReiterated RatingBuy$408.00HighView Rating Details
1/25/2018BMO Capital MarketsReiterated RatingBuyHighView Rating Details
1/25/2018Robert W. BairdReiterated RatingNeutral -> HoldHighView Rating Details
1/25/2018Goldman Sachs GroupSet Price TargetBuy$390.00MediumView Rating Details
1/21/2018BarclaysReiterated RatingBuy$395.00MediumView Rating Details
1/16/2018CitigroupReiterated RatingOutperform$350.00 -> $380.00MediumView Rating Details
1/2/2018Piper Jaffray CompaniesReiterated RatingBuyHighView Rating Details
12/30/2017NomuraBoost Price TargetBuy$355.00 -> $420.00N/AView Rating Details
11/28/2017Sanford C. BernsteinSet Price TargetBuy$310.00 -> $318.00MediumView Rating Details
10/24/2017Cantor FitzgeraldReiterated RatingHold$279.00N/AView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$402.00N/AView Rating Details
10/18/2017Bank of AmericaBoost Price TargetBuy$358.00 -> $365.00N/AView Rating Details
10/17/2017Morgan StanleyReiterated RatingBuyN/AView Rating Details
10/17/2017Stifel NicolausUpgradeHold -> Buy$300.00 -> $415.00N/AView Rating Details
9/21/2017Raymond James FinancialDowngradeStrong-Buy -> Market Perform$244.28 -> $319.00LowView Rating Details
7/26/2017Leerink SwannReiterated RatingMarket Perform$304.00 -> $338.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$223.03 -> $345.00N/AView Rating Details
8/2/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
6/8/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Biogen (NASDAQ:BIIB) Earnings History and Estimates Chart

Earnings by Quarter for Biogen (NASDAQ:BIIB)

Biogen (NASDAQ BIIB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/23/2018$5.89N/AView Earnings Details
1/25/2018Q4 2017$5.44$5.26$3.08 billion$3.31 billionViewListenView Earnings Details
10/24/2017Q3 2017$5.70$6.31$3.05 billion$3.08 billionViewN/AView Earnings Details
7/25/2017Q2 2017$4.36$5.04$2.81 billion$3.08 billionViewN/AView Earnings Details
4/25/2017Q1 2017$4.97$5.20$2.73 billion$2.81 billionViewN/AView Earnings Details
1/26/2017Q416$4.96$5.04$2.94 billion$2.87 billionViewN/AView Earnings Details
10/26/2016Q316$4.97$5.19$2.91 billion$2.96 billionViewListenView Earnings Details
7/21/2016Q216$4.69$5.21$2.79 billion$2.89 billionViewListenView Earnings Details
4/21/2016Q116$4.47$4.79$2.75 billion$2.73 billionViewListenView Earnings Details
1/27/2016Q415$4.08$4.50$2.70 billion$2.84 billionViewListenView Earnings Details
10/21/2015Q315$3.80$4.48$2.65 billion$2.39 billionViewListenView Earnings Details
7/24/2015Q215$4.10$4.22$2.71 billion$2.59 billionViewListenView Earnings Details
4/24/2015Q115$3.91$3.82$2.66 billion$2.56 billionViewListenView Earnings Details
1/29/2015Q414$3.74$4.09$2.64 billion$2.60 billionViewListenView Earnings Details
10/22/2014Q3$3.22$3.80$2.48 billion$2.50 billionViewListenView Earnings Details
7/23/2014Q214$2.80$3.49$2.14 billion$2.42 billionViewListenView Earnings Details
4/23/2014Q114$2.56$2.47$2.00 billion$2.10 billionViewListenView Earnings Details
1/29/2014Q413$2.27$2.34$1.93 billion$2.00 billionViewListenView Earnings Details
10/28/2013Q313$2.10$2.35$1.78 billion$1.83 billionViewListenView Earnings Details
7/25/2013Q2 2013$1.93$2.30$1.62 billion$1.70 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.63$1.97$1.41 billion$1.40 billionViewListenView Earnings Details
1/28/2013Q4 2012$1.46$1.40$1.38 billion$1.40 billionViewListenView Earnings Details
10/25/2012$1.60$1.91ViewN/AView Earnings Details
7/24/2012$1.56$1.82ViewN/AView Earnings Details
5/1/2012$1.49$1.40ViewN/AView Earnings Details
1/31/2012$1.49$1.51ViewN/AView Earnings Details
10/28/2011$1.52$1.61ViewN/AView Earnings Details
7/26/2011$1.36$1.36ViewN/AView Earnings Details
4/21/2011$1.41$1.43ViewN/AView Earnings Details
2/1/2011$1.23$1.42ViewN/AView Earnings Details
10/26/2010Q3 2010$1.20$1.33ViewN/AView Earnings Details
7/20/2010Q2 2010$1.08$1.28ViewN/AView Earnings Details
4/20/2010Q1 2010$1.12$1.05ViewN/AView Earnings Details
2/9/2010Q4 2009$1.05$1.17ViewN/AView Earnings Details
10/20/2009Q3 2009$1.02$1.09ViewN/AView Earnings Details
7/16/2009Q2 2009$0.89$0.73ViewN/AView Earnings Details
4/16/2009Q1 2009$1.00$1.05ViewN/AView Earnings Details
2/6/2009Q4 2008$0.88$0.91ViewN/AView Earnings Details
10/21/2008Q3 2008$0.89$0.95ViewN/AView Earnings Details
7/22/2008Q2 2008$0.83$0.91ViewN/AView Earnings Details
4/23/2008Q1 2008$0.78$0.82ViewN/AView Earnings Details
2/6/2008Q4 2007$0.79$0.89ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Biogen (NASDAQ:BIIB) Earnings Estimates

2018 EPS Consensus Estimate: $24.88
2019 EPS Consensus Estimate: $26.77
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185$5.81$6.04$5.97
Q2 20185$6.24$6.41$6.33
Q3 20185$6.19$6.45$6.30
Q4 20185$6.05$6.49$6.28
Q1 20192$6.30$6.30$6.30
Q2 20192$6.53$6.71$6.62
Q3 20191$6.92$6.92$6.92
Q4 20191$6.93$6.93$6.93
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Biogen (NASDAQ:BIIB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Biogen (NASDAQ BIIB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.25%
Institutional Ownership Percentage: 89.20%
Insider Trades by Quarter for Biogen (NASDAQ:BIIB)
Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Biogen (NASDAQ BIIB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/20/2018Alfred SandrockEVPSell743$292.00$216,956.006,553View SEC Filing  
2/15/2018Alfred SandrockEVPSell1,294$298.85$386,711.907,296View SEC Filing  
1/9/2018Robert W PangiaDirectorSell5,832$329.65$1,922,518.8023,539View SEC Filing  
12/29/2017Michel VounatsosCEOBuy780$320.55$250,029.00View SEC Filing  
12/29/2017Michel VounatsosCEOBuy780$320.55$250,029.004,879View SEC Filing  
11/29/2017Alexander J DennerDirectorBuy30,000$317.36$9,520,800.0010,029View SEC Filing  
7/25/2017Susan H AlexanderEVPSell4,974$290.01$1,442,509.7422,258View SEC Filing  
7/19/2017Susan H AlexanderEVPSell7,758$285.00$2,211,030.0027,232View SEC Filing  
6/9/2017Brian S PosnerDirectorSell1,084$256.31$277,840.046,330View SEC Filing  
5/1/2017Michel VounatsosCEOBuy1,402$271.35$380,432.70View SEC Filing  
4/27/2017Alexander J. DennerDirectorBuy73,858$278.50$20,569,453.00View SEC Filing  
4/25/2017Paul J ClancyVPSell9,892$290.00$2,868,680.0010,813View SEC Filing  
4/3/2017Alfred SandrockCMOSell1,981$274.08$542,952.487,060View SEC Filing  
3/13/2017Paul J ClancyVPSell9,891$291.55$2,883,721.0520,705View SEC Filing  
2/27/2017Michel VounatsosCEOBuy1,333$285.39$380,424.87View SEC Filing  
1/9/2017Robert W PangiaDirectorSell5,450$295.39$1,609,875.5022,078View SEC Filing  
10/4/2016Adriana KaraboutisEVPSell262$311.94$81,728.287,579View SEC Filing  
10/3/2016Adriana KaraboutisEVPSell380$313.00$118,940.007,172View SEC Filing  
9/22/2016Caroline DorsaDirectorSell27,570$314.00$8,656,980.0019,663View SEC Filing  
7/21/2016George A ScangosCEOSell157$280.00$43,960.0054,779View SEC Filing  
6/6/2016Adam KoppelEVPSell555$290.00$160,950.002,402View SEC Filing  
6/3/2016George A ScangosCEOSell842$290.00$244,180.0054,936View SEC Filing  
6/1/2016George A ScangosCEOSell3,855$289.74$1,116,947.7056,265View SEC Filing  
5/25/2016George A ScangosCEOSell157$280.00$43,960.0059,633View SEC Filing  
5/2/2016George A ScangosCEOSell487$274.74$133,798.3859,790View SEC Filing  
4/6/2016Adam KoppelEVPSell102$275.00$28,050.001,848View SEC Filing  
4/6/2016George A ScangosCEOSell157$280.00$43,960.0060,277View SEC Filing  
4/1/2016George A ScangosCEOSell487$258.83$126,050.2160,434View SEC Filing  
3/1/2016George A ScangosCEOSell487$261.37$127,287.1960,921View SEC Filing  
2/25/2016Adriana KaraboutisEVPSell84$261.90$21,999.608,127View SEC Filing  
2/25/2016Alfred SandrockCMOSell183$261.90$47,927.707,990View SEC Filing  
2/17/2016Alfred SandrockChief Medical OfficerSell722$256.16$184,947.527,990View SEC Filing  
2/17/2016George A ScangosCEOSell487$256.16$124,749.9259,848View SEC Filing  
2/9/2016Alfred SandrockChief Medical OfficerSell852$246.54$210,052.087,740View SEC Filing  
12/4/2015Alfred SandrockCMOSell441$277.00$122,157.007,740View SEC Filing  
10/23/2015Alexander J DennerDirectorBuy310,000$277.47$86,015,700.007,890View SEC Filing  
7/27/2015Stelios PapadopoulosDirectorBuy10,000$304.88$3,048,800.00View SEC Filing  
6/19/2015Douglas E WilliamsEVPSell3,841$410.00$1,574,810.00View SEC Filing  
6/1/2015George A ScangosCEOSell1,362$398.87$543,260.94View SEC Filing  
4/1/2015George A ScangosCEOSell1,362$423.20$576,398.40View SEC Filing  
3/25/2015John CoxEVPSell12,010$449.06$5,393,210.60View SEC Filing  
3/20/2015Eric K RowinskyDirectorSell11,667$475.00$5,541,825.00View SEC Filing  
3/19/2015Eric K RowinskyDirectorSell2,333$436.14$1,017,514.62View SEC Filing  
3/17/2015Eric K RowinskyDirectorSell4,667$425.45$1,985,575.15View SEC Filing  
3/10/2015Robert W PangiaDirectorSell3,625$413.40$1,498,575.00View SEC Filing  
3/2/2015Alfred SandrockSVPSell3,174$409.49$1,299,721.26View SEC Filing  
2/17/2015Steven H HoltzmanEVPSell2,128$389.11$828,026.08View SEC Filing  
2/10/2015Alfred SandrockSVPSell1,143$398.11$455,039.73View SEC Filing  
2/2/2015Kenneth DipietroEVPSell1,656$389.03$644,233.68View SEC Filing  
12/15/2014Spyridon Artavanis-TsakonasSVPSell1,981$346.50$686,416.50View SEC Filing  
12/2/2014Steven H HoltzmanEVPSell1,749$335.65$587,051.85View SEC Filing  
11/11/2014Steven H HoltzmanEVPSell1,750$330.00$577,500.00View SEC Filing  
11/3/2014George A ScangosCEOSell1,128$320.78$361,839.84View SEC Filing  
10/1/2014George A ScangosCEOSell1,127$330.97$373,003.19View SEC Filing  
10/1/2014Steven H HoltzmanEVPSell1,750$330.97$579,197.50View SEC Filing  
8/1/2014George A ScangosCEOSell1,128$332.93$375,545.04View SEC Filing  
7/16/2014George A ScangosCEOSell12,316$312.37$3,847,148.92View SEC Filing  
5/19/2014Steven HoltzmanEVPSell1,221$289.15$353,052.155,749View SEC Filing  
5/1/2014George ScangosCEOSell2,123$285.56$606,243.8824,019View SEC Filing  
4/17/2014Steven HoltzmanEVPSell1,221$291.00$355,311.006,970View SEC Filing  
4/1/2014George ScangosCEOSell2,123$308.42$654,775.6626,142View SEC Filing  
4/1/2014Robert PangiaDirectorSell6,250$308.42$1,927,625.0014,003View SEC Filing  
3/31/2014Brian PosnerDirectorSell3,000$296.76$890,280.006,435View SEC Filing  
3/20/2014Caroline DorsaDirectorSell10,000$348.88$3,488,800.0014,468View SEC Filing  
3/19/2014Douglas WilliamsEVPSell3,505$352.29$1,234,776.457,976View SEC Filing  
3/17/2014Steven HoltzmanEVPSell1,221$334.83$408,827.438,191View SEC Filing  
3/11/2014Stuart KingsleyEVPSell8,428$336.83$2,838,803.243,511View SEC Filing  
3/3/2014George ScangosCEOSell2,942$335.79$987,894.1854,389View SEC Filing  
2/26/2014Alfred SandrockSVPSell1,048$342.17$358,594.1621,407View SEC Filing  
2/18/2014Steven HoltzmanEVPSell1,222$327.90$400,693.809,412View SEC Filing  
2/13/2014Kenneth DipietroEVPSell1,290$316.81$408,684.90View SEC Filing  
2/11/2014Alfred SandrockSVPSell2,085$314.31$655,336.3513,667View SEC Filing  
2/11/2014George ScangosCEOSell2,456$314.31$771,945.3652,961View SEC Filing  
2/4/2014Kenneth DipietroEVPSell1,655$299.01$494,861.55View SEC Filing  
1/21/2014Eric RowinskyDirectorSell2,020$310.09$626,381.8010,440View SEC Filing  
1/15/2014Lynn SchenkDirectorSell1,000$297.48$297,480.003,325View SEC Filing  
1/8/2014William YoungDirectorSell15,000$285.11$4,276,650.0018,509View SEC Filing  
1/6/2014Robert PangiaDirectorSell6,250$278.03$1,737,687.5014,003View SEC Filing  
12/2/2013Lynn SchenkDirectorSell1,000$291.71$291,710.003,325View SEC Filing  
11/22/2013Raymond PawlickiSVPSell4,000$288.00$1,152,000.008,710View SEC Filing  
11/1/2013George A ScangosCEOSell2,239$245.57$549,831.23View SEC Filing  
11/1/2013Lynn SchenkDirectorSell1,000$245.00$245,000.00View SEC Filing  
10/22/2013Alfred SandrockSVPSell15,030$250.11$3,759,153.30View SEC Filing  
9/18/2013Paul ClancyCFOSell26,785$245.00$6,562,325.007,087View SEC Filing  
9/17/2013Steven HoltzmanEVPSell3,501$238.98$836,668.984,885View SEC Filing  
9/16/2013Paul ClancyCFOSell99,030$238.27$23,595,878.107,087View SEC Filing  
9/16/2013Raymond PawlickiSVPSell4,000$238.03$952,120.008,710View SEC Filing  
9/3/2013George ScangosCEOSell2,239$214.40$480,041.6043,522View SEC Filing  
8/26/2013Douglas WilliamsEVPSell4,368$211.35$923,176.804,571View SEC Filing  
8/1/2013George A ScangosCEOSell2,239$218.82$489,937.98View SEC Filing  
7/16/2013George A ScangosCEOSell2,239$223.94$501,401.66View SEC Filing  
6/14/2013Alexander J DennerDirectorSell2,900$212.00$614,800.00View SEC Filing  
6/11/2013Brian S PosnerDirectorSell2,020$219.62$443,632.40View SEC Filing  
6/10/2013Lynn SchenkDirectorSell2,000$225.82$451,640.00View SEC Filing  
6/3/2013George A ScangosCEOSell1,598$234.16$374,187.68View SEC Filing  
6/3/2013Stephen A SherwinDirectorSell12,825$233.26$2,991,559.50View SEC Filing  
5/28/2013Robert W PangiaDirectorSell5,900$237.23$1,399,657.00View SEC Filing  
12/27/2012Alexander J DennerDirectorSell7,980$148.62$1,185,987.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biogen (NASDAQ BIIB) News Headlines

Source:
DateHeadline
Head-To-Head Contrast: Fortress Biotech (FBIO) & Biogen (BIIB)Head-To-Head Contrast: Fortress Biotech (FBIO) & Biogen (BIIB)
www.americanbankingnews.com - February 22 at 10:12 AM
Insider Selling: Biogen Inc (BIIB) EVP Sells 743 Shares of StockInsider Selling: Biogen Inc (BIIB) EVP Sells 743 Shares of Stock
www.americanbankingnews.com - February 21 at 6:30 PM
Biogen chief says market overreacted to increased enrollment in aducanumab studies; shares up 1% premarket - Seeking AlphaBiogen chief says market overreacted to increased enrollment in aducanumab studies; shares up 1% premarket - Seeking Alpha
seekingalpha.com - February 21 at 8:19 AM
Agree To Purchase Biogen At $270, Earn 9.1% Annualized Using Options - NasdaqAgree To Purchase Biogen At $270, Earn 9.1% Annualized Using Options - Nasdaq
www.nasdaq.com - February 21 at 8:19 AM
[$$] Biogen CEO Calls Share Slump an Overreaction to Alzheimer’s Trial[$$] Biogen CEO Calls Share Slump an Overreaction to Alzheimer’s Trial
finance.yahoo.com - February 21 at 8:18 AM
Biogen Inc (BIIB) EVP Alfred Sandrock Sells 1,294 SharesBiogen Inc (BIIB) EVP Alfred Sandrock Sells 1,294 Shares
www.americanbankingnews.com - February 20 at 9:30 PM
Biogen CEO Calls Share Slump an Overreaction to Alzheimer’s TrialBiogen CEO Calls Share Slump an Overreaction to Alzheimer’s Trial
www.wsj.com - February 20 at 5:48 PM
[$$] Biogen CEO Calls Share Slump an Overreaction to Alzheimers Trial[$$] Biogen CEO Calls Share Slump an Overreaction to Alzheimer's Trial
finance.yahoo.com - February 20 at 5:48 PM
Buy Biogen Stock on the Dip?Buy Biogen Stock on the Dip?
finance.yahoo.com - February 19 at 8:14 AM
Hold for Biogen (BIIB) This Week - Investorplace.comHold for Biogen (BIIB) This Week - Investorplace.com
investorplace.com - February 18 at 8:15 AM
$3.14 Billion in Sales Expected for Biogen Inc (BIIB) This Quarter$3.14 Billion in Sales Expected for Biogen Inc (BIIB) This Quarter
www.americanbankingnews.com - February 18 at 2:04 AM
Biogen (BIIB) Downgraded by BidaskClubBiogen (BIIB) Downgraded by BidaskClub
www.americanbankingnews.com - February 17 at 11:36 PM
Biogen is Now OversoldBiogen is Now Oversold
www.nasdaq.com - February 17 at 8:12 AM
Zacks: Analysts Anticipate Biogen Inc (BIIB) to Post $5.94 Earnings Per ShareZacks: Analysts Anticipate Biogen Inc (BIIB) to Post $5.94 Earnings Per Share
www.americanbankingnews.com - February 16 at 9:14 PM
Notable Friday Option Activity: COHU, BIIB, FDXNotable Friday Option Activity: COHU, BIIB, FDX
www.nasdaq.com - February 16 at 5:19 PM
Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimers DrugsArgus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs
finance.yahoo.com - February 16 at 5:19 PM
How Biogen Inc (NASDAQ:BIIB) Delivered A Better ROE Than Its IndustryHow Biogen Inc (NASDAQ:BIIB) Delivered A Better ROE Than Its Industry
finance.yahoo.com - February 16 at 5:19 PM
Hold for Biogen (BIIB) This WeekHold for Biogen (BIIB) This Week
investorplace.com - February 16 at 12:09 PM
Biogen (BIIB) Downgraded by Argus to "Hold"Biogen (BIIB) Downgraded by Argus to "Hold"
www.americanbankingnews.com - February 16 at 10:12 AM
BIIB Makes Notable Cross Below Critical Moving Average - NasdaqBIIB Makes Notable Cross Below Critical Moving Average - Nasdaq
www.nasdaq.com - February 16 at 8:16 AM
U.S. FDA looks to pave way for earlier-stage Alzheimers drugsU.S. FDA looks to pave way for earlier-stage Alzheimer's drugs
finance.yahoo.com - February 16 at 8:16 AM
FDA Sets the Stage for Earlier-Stage Alzheimer's TreatmentsFDA Sets the Stage for Earlier-Stage Alzheimer's Treatments
finance.yahoo.com - February 16 at 8:16 AM
Why Biogen May Seek A Merger In The Wake Of Alzheimer's WorriesWhy Biogen May Seek A Merger In The Wake Of Alzheimer's Worries
finance.yahoo.com - February 15 at 5:22 PM
William Blair Reaffirms Buy Rating for Biogen (BIIB)William Blair Reaffirms Buy Rating for Biogen (BIIB)
www.americanbankingnews.com - February 15 at 5:06 PM
Canaccord Genuity Analysts Give Biogen (BIIB) a $350.00 Price TargetCanaccord Genuity Analysts Give Biogen (BIIB) a $350.00 Price Target
www.americanbankingnews.com - February 15 at 3:58 PM
BIIB Makes Notable Cross Below Critical Moving AverageBIIB Makes Notable Cross Below Critical Moving Average
www.nasdaq.com - February 15 at 9:45 AM
Biogen shares plunge after company makes change to Alzheimer’s drug trialsBiogen shares plunge after company makes change to Alzheimer’s drug trials
finance.yahoo.com - February 15 at 9:45 AM
Biogen: S&P 500’s Top Loser on February 14Biogen: S&P 500’s Top Loser on February 14
finance.yahoo.com - February 15 at 9:45 AM
Dow's Merck Failed On Alzheimer Drug But It Shouldn't Hurt BiogenDow's Merck Failed On Alzheimer Drug But It Shouldn't Hurt Biogen
finance.yahoo.com - February 14 at 3:51 PM
Merck (MRK) Halts Another Late Stage Study on Alzheimer'sMerck (MRK) Halts Another Late Stage Study on Alzheimer's
finance.yahoo.com - February 14 at 3:51 PM
Biotech Developer Stock Price Risks & Returns: An Understanding TodayBiotech Developer Stock Price Risks & Returns: An Understanding Today
seekingalpha.com - February 12 at 3:42 PM
Major Biotechs See Rising Tide of Short InterestMajor Biotechs See Rising Tide of Short Interest
www.msn.com - February 12 at 9:33 AM
Norway to buy Biogens Spinraza medicine - broadcaster NRKNorway to buy Biogen's Spinraza medicine - broadcaster NRK
finance.yahoo.com - February 12 at 9:33 AM
Biogen (BIIB) Upgraded to Buy at Credit Suisse GroupBiogen (BIIB) Upgraded to Buy at Credit Suisse Group
www.americanbankingnews.com - February 8 at 7:48 PM
BRIEF-Biogen Reports Top-Line Results From Phase 2b Study Of Natalizumab In Acute Ischemic StrokeBRIEF-Biogen Reports Top-Line Results From Phase 2b Study Of Natalizumab In Acute Ischemic Stroke
www.reuters.com - February 8 at 3:40 PM
Biogen Halts Tysabri Development in Stroke as Study FailsBiogen Halts Tysabri Development in Stroke as Study Fails
finance.yahoo.com - February 8 at 3:40 PM
Exploring Bioverativ’s Business Profile and Market PresenceExploring Bioverativ’s Business Profile and Market Presence
finance.yahoo.com - February 8 at 8:09 AM
What Should We Expect From Biogen Inc’s (NASDAQ:BIIB) Earnings Over The Next Year?What Should We Expect From Biogen Inc’s (NASDAQ:BIIB) Earnings Over The Next Year?
finance.yahoo.com - February 8 at 8:09 AM
Biogen's Tysabri Fails In Stroke Trial — Coming As 'No Surprise'Biogen's Tysabri Fails In Stroke Trial — Coming As 'No Surprise'
finance.yahoo.com - February 8 at 8:09 AM
Biogen (BIIB) Earns Buy Rating from JPMorgan Chase & Co.Biogen (BIIB) Earns Buy Rating from JPMorgan Chase & Co.
www.americanbankingnews.com - February 8 at 7:50 AM
Biogen (BIIB) Given Hold Rating at Canaccord GenuityBiogen (BIIB) Given Hold Rating at Canaccord Genuity
www.americanbankingnews.com - February 8 at 12:42 AM
Biogen stock declines after stroke trial failureBiogen stock declines after stroke trial failure
finance.yahoo.com - February 7 at 9:25 AM
Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic StrokeBiogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke
finance.yahoo.com - February 7 at 9:25 AM
Biogen stops testing Tysabri to treat stroke after study failsBiogen stops testing Tysabri to treat stroke after study fails
finance.yahoo.com - February 7 at 9:25 AM
Biogen to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceBiogen to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 6 at 9:16 AM
Why Biogen Stock Can Continue To RiseWhy Biogen Stock Can Continue To Rise
finance.yahoo.com - February 5 at 3:39 PM
Billionaire Fund Managers Are Bullish On These Biotech StocksBillionaire Fund Managers Are Bullish On These Biotech Stocks
finance.yahoo.com - February 5 at 9:25 AM
Biogen (BIIB) Earns "Buy" Rating from MizuhoBiogen (BIIB) Earns "Buy" Rating from Mizuho
www.americanbankingnews.com - February 5 at 12:28 AM
Biogen Inc (BIIB) Files 10-K for the Fiscal Year Ended on December 31, 2017Biogen Inc (BIIB) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 2 at 9:10 AM
Contrasting Biogen (BIIB) & Novus Therapeutics (NVUS)Contrasting Biogen (BIIB) & Novus Therapeutics (NVUS)
www.americanbankingnews.com - February 1 at 3:20 AM

SEC Filings

Biogen (NASDAQ:BIIB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Biogen (NASDAQ:BIIB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Biogen (NASDAQ BIIB) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.